CapnoPharm is a Germany-based biotechnology company and global leader in locoregional cancer therapies using pressurized aerosol drug delivery. Built on the PIPAC invention, the company develops proprietary drug–device combinations that integrate CE-certified nebulizers with reformulated anticancer drugs for targeted treatment of peritoneal and pleural cancers.

Leveraging strong clinical evidence, a robust IP portfolio, and a profitable medical device platform, CapnoPharm is advancing its lead assets, CapnoDC^® and CapnoXal^®, toward EMA and FDA approval aiming to improve outcomes and quality of life for patients with peritoneal and pleural cancer-